Back to Search Start Over

Effect of different conditioning regimens on survival and engraftment for children with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoeitic stem cell transplantation: A single institution experience

Authors :
Bruce Crooks
Rae Brager
Muhammad Ali
Paul Gibson
Sheila Weitzman
Kuang-Yueh Chiang
Conrad V. Fernandez
Donna A. Wall
Joerg Krueger
Adam Gassas
Ahmed Naqvi
Tal Schechter
Salah Ali
Source :
Pediatric Blood & Cancer. 67
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Background Hemophagocytic lymphohistiocytosis (HLH), a rare hyperinflammatory immuneregulatory disorder, is a challenge in hematopoietic stem cell transplantation (HSCT) because of the high rate of mixed chimerism, relapse, and graft failure (GF) unless intensive myeloablative regimens are used. However, historically conventional myeloablative regimens (conv MA) are associated with high toxicity and mortality. Procedure We retrospectively compared transplant outcomes between three preparative regimens of varying intensities: Conv MA (n = 15), reduced-intensity conditioning (RIC, n = 12), and a treosulfan-based reduced-toxicity conditioning (RTC, n = 9). Results Patients in the RIC cohort had a higher incidence of mixed donor chimerism and five patients (42%) developed secondary GF (P = .002) compared to the other two regimens. There was a higher incidence of veno-occlusive disease and intensive care unit (ICU) admissions in the Conv MA cohort. With the RTC regimen, there was a similar 2-year overall survival (89, 73, and 83%; P = .87), but improved compound EFS (lack of relapse, GF, second transplant or additional donor cell infusions, or death; 89, 73, and 42%, P = .041) in RTC, Conv MA, and RIC regimen, respectively. Conclusions The intensity of the preparative regimen has a significant impact on outcome of HSCT for HLH. The newly described treosulfan-based RTC provides for a stable graft with a reasonable toxicity profile.

Details

ISSN :
15455017 and 15455009
Volume :
67
Database :
OpenAIRE
Journal :
Pediatric Blood & Cancer
Accession number :
edsair.doi.dedup.....5db4542f1e10853cbbca78d126304264